[
  {
    "ts": null,
    "headline": "These companies are emerging as potential winners in Trump’s trade war",
    "summary": "These companies are emerging as potential winners in Trump’s trade war",
    "url": "https://finnhub.io/api/news?id=3730d7ab97a78fdc13b9ea1cffca7e0ca2138a8dc8596e145bce054cf7f1dd0e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746190920,
      "headline": "These companies are emerging as potential winners in Trump’s trade war",
      "id": 134193184,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "These companies are emerging as potential winners in Trump’s trade war",
      "url": "https://finnhub.io/api/news?id=3730d7ab97a78fdc13b9ea1cffca7e0ca2138a8dc8596e145bce054cf7f1dd0e"
    }
  },
  {
    "ts": null,
    "headline": "Why The Low Payout Ratio Did Not Stop The Dividend Cut For Organon",
    "summary": "Organon stock cut their dividend by over 90%. There are lessons here for all income investors. Click here to find out what income investors need to know.",
    "url": "https://finnhub.io/api/news?id=4e16ad76cd7fda98777b06d445f7f29349431cdcd21668fec46e78c5e347c473",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746180010,
      "headline": "Why The Low Payout Ratio Did Not Stop The Dividend Cut For Organon",
      "id": 134184342,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1460500012/image_1460500012.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Organon stock cut their dividend by over 90%. There are lessons here for all income investors. Click here to find out what income investors need to know.",
      "url": "https://finnhub.io/api/news?id=4e16ad76cd7fda98777b06d445f7f29349431cdcd21668fec46e78c5e347c473"
    }
  },
  {
    "ts": null,
    "headline": "Inhibikase Therapeutics: A Hold With Uncertain Prospects In PAH",
    "summary": "Inhibikase (IKT) pivots to IkT-001Pro for PAH amid competition like Merckâs sotatercept. Backed by $97.5M, results will determine its future competitiveness. See more.",
    "url": "https://finnhub.io/api/news?id=054c80caa8729089a0c860ac3f3984272f6b337145704305f526bef785c84c87",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746162451,
      "headline": "Inhibikase Therapeutics: A Hold With Uncertain Prospects In PAH",
      "id": 134182320,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1343361460/image_1343361460.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Inhibikase (IKT) pivots to IkT-001Pro for PAH amid competition like Merckâs sotatercept. Backed by $97.5M, results will determine its future competitiveness. See more.",
      "url": "https://finnhub.io/api/news?id=054c80caa8729089a0c860ac3f3984272f6b337145704305f526bef785c84c87"
    }
  }
]